相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification
Cathy B. Moelans et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast
Semir Vranic et al.
MODERN PATHOLOGY (2010)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)
John M. S. Bartlett et al.
LANCET ONCOLOGY (2010)
Real-Time RT-PCR Analysis for Evaluating the Her2/neu Status in Breast Cancer
M. Cuadros et al.
PATHOBIOLOGY (2010)
Treatment of metastatic breast cancer: looking towards the future
Surabhi Amar et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Copy Number Alterations that Predict Metastatic Capability of Human Breast Cancer
Yi Zhang et al.
CANCER RESEARCH (2009)
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
Guido Sauter et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
Caterina Marchio et al.
JOURNAL OF PATHOLOGY (2009)
Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma
Uma Krishnamurti et al.
MODERN PATHOLOGY (2009)
Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
I-Tien Yeh et al.
MODERN PATHOLOGY (2009)
Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response
Monica M. Reinholz et al.
LANCET ONCOLOGY (2009)
Cardiac toxicity of ErbB2-targeted therapies: What do we know?
Edith A. Perez
CLINICAL BREAST CANCER (2008)
Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing
Isabelle Vanden Bempt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Whole genome SNP arrays as a potential diagnostic tool for the detection of characteristic chromosomal aberrations in renal epithelial tumors
Federico A. Monzon et al.
MODERN PATHOLOGY (2008)
The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
C. L. Hyun et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast - A single institution experience
Raymond R. Tubbs et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+in immunohistochemical analysis
R. Merola et al.
EUROPEAN JOURNAL OF CANCER (2006)
Polysomy 17 in HER-2/neu status elaboration in breast cancer: Effect on daily practice
Y Ma et al.
CLINICAL CANCER RESEARCH (2005)
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
M Salido et al.
BREAST CANCER RESEARCH (2005)
Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay
D Varshney et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2004)
Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma
AD Watters et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Aneusomy 17 in breast cancer: Its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status
SJ Wang et al.
MODERN PATHOLOGY (2002)
Evaluating HER2 amplification and overexpression in breast cancer
JMS Bartlett et al.
JOURNAL OF PATHOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
